Common supplement tested to tame debilitating blood cancer symptoms
NCT ID NCT05123365
Summary
This study aims to find the best dose of N-Acetylcysteine (N-AC), a common supplement, to help reduce symptoms in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It will enroll 27 adults with ET, PV, or MF who have significant symptom burden. The main goal is to identify a dose that is both safe and effective at lowering patients' overall symptom scores over an 8-week period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
ACTIVE_NOT_RECRUITINGOrange, California, 92868, United States
-
University of California, Irvine
RECRUITINGIrvine, California, 92617, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.